Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003751 · ClinicalTrials.gov registry record · Phase 2
Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 9
- Study locations
NCT00003751 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 40 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (78% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT00003751, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
Conditions Studied
Interventions
- RADIATION radiation therapy
- DRUG penicillamine
Study Locations (9)
Alabama
- University of Alabama Comprehensive Cancer Center - Birmingham
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Emory University School of Medicine - Atlanta
Maryland
- Johns Hopkins Oncology Center - Baltimore
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Michigan
- Henry Ford Hospital - Detroit
North Carolina
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center - Winston-Salem
Pennsylvania
- University of Pennsylvania Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1999-03 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003751
The ClinicalTrials.gov registry entry for NCT00003751 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (78% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.
NCT00003751 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Alabama, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00003751 about?
NCT00003751 is a clinical study titled "Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma". RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblas...
What is the current status of trial NCT00003751?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1999-03. Estimated completion is 2005-07.
What conditions does trial NCT00003751 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00003751?
The interventions under investigation include: radiation therapy (RADIATION), penicillamine (DRUG).
Who is sponsoring clinical trial NCT00003751?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003751 being conducted?
This trial has 9 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
COMPLETED · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.